Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.